Penny stocks are a viable way to see some big returns at a time
of market uncertainty. That's because small-cap penny stocks can
see big gains very quickly, while larger stocks tend to be slower
Here are 7 penny stocks in the health care sector each trading
at under $2 a share as of this writing. Although these health care
stocks may not be industry giants, they have shown long-term return
potential for investors with strong year to date market
Antares Pharma Inc. (
Antares Pharma, Inc.
) is a pharmaceutical company that focuses on self-injection
pharmaceutical products and technologies and gel-based products.
This small cap pharmaceutical company saw its revenue increase 57%
for the first six months of 2010 compared to the same period in
2009. Another positive sign from AIS shares is the +64.58% the
stock has gained from its value this time last summer.
Arrowhead Research Corp. (
Arrowhead Research Corporation
) is a development stage nanotechnology company focused on the
electronics and biotech industries. The California-based company
has managed to outperform EPS estimates for three consecutive
quarters and shares have improved from a weak start in 2010, with
ARWR up +77% since mid-March of this year.
CombinatoRx Inc. (CRXX)
) is a biopharmaceutical company engaged in developing drug
candidates with a focus on the treatment of pain and inflammation.
Year to date, CRXX shares have surprised investors with an upward
trend that eclipses the unimpressive broader market performances.
Since the start of 2010, shares have gained +64.46%.
Cyclacel Pharmaceuticals (
Cyclacel Pharmaceuticals, Inc.
) is a development-stage biopharmaceutical company engaged in the
discovery, development and commercialization of mechanism-targeted
drugs to treat human cancers and other serious disorders. With
shares up nearly +50% since January, CYCC could end up being a
bargain at its current price.
Inhibitex Inc. (
) is a biopharmaceutical company focused on the development of
differentiated anti-infective products to prevent and treat serious
infections. This small cap pharma stock is showing some good growth
potential with year to date performance at +68.48%. In addition to
shares surging this summer, prospective investors should note that
INHX has beat earnings estimates for three of the past four
Rexahn Pharmaceuticals (
Rexahn Pharmaceuticals, Inc.
) is a clinical stage biopharmaceutical company developing and
seeking to deliver cures for cancer and disorders of the central
nervous system in patients. Rexahn's three clinical stage drug
candidates are Archexin, Serdaxin, and Zoraxel. With RNN stock up
+75% since the start of the year, shareholders may be finding this
Rockville, Md.-based company as the cure for their market ills.
YM Bio Sciences Inc. (YMI)
YM BioSciences Inc.
) is a biopharmaceutical company engaged in the development of
products primarily for the treatment of patients with cancer. The
Canadian company's portfolio of products in active clinical
development includes one anti-cancer agent targeting more than 10
different tumors and/or stages of cancer, and an
inhalation-delivery approach to treat acute pain, including cancer
pain. YMI stocks has had some ups and downs over recent months but
overall growth looks positive, with shares more than +40% ahead of
where they were at this time last August.
As of this writing, Louis Navellier did not own a position in
any of the stocks owned here.
The One ETF to Own Now.
Louis Navellier's new profit guide reveals the hottest ETF to
buy now, plus details his breakthrough new strategy designed to
help you lock in short-term gains from ETFs in sectors just
heating up, and then when those sectors are on fire, grab
money-doubling profits from the fastest-moving individual stocks.
Get your FREE copy here!